anti-B7-H3 CAR T-cell therapy (Soochow T-Maximun Biotechnology/Second Affiliated Hospital of Soochow University)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameanti-B7-H3 CAR T-cell therapy (Soochow T-Maximun Biotechnology/Second Affiliated Hospital of Soochow University)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionCD276 antigen modulators
TargetsCD276 antigen
Therapy Area/IndicationsGlioma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaClinical
Originator CompaniesT-Maximum Pharmaceutical (Suzhou) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSecond Affiliated Hospital Of Suzhou UniversityT-Maximum Pharmaceutical (Suzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsGlioma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A